+ |
midostaurin | down-regulates activity
chemical inhibition
|
FLT3 |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-258247 |
|
|
in vitro |
|
pmid |
sentence |
22037378 |
Our data set represents the most detailed comprehensive assessment of the reactivity of known and clinical kinase inhibitors across the kinome published to date. | The data also show that for at least 15 of the 27 kinases that are the primary, intended targets for the compounds tested and that are represented in the assay panel, selective inhibitors, as assessed by both absolute selectivity across the kinome and selectivity relative to the primary target, are among the 72 tested here. |
|
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-256308 |
|
|
in vitro |
|
pmid |
sentence |
12124173 |
PKC412 is a potent inhibitor of mutant FLT3 and is a candidate for testing as an antileukemia agent in AML patients with mutant FLT3 receptors. |
|
Publications: |
2 |
Organism: |
In Vitro |
Pathways: | Acute Myeloid Leukemia, FLT3 in AML |
+ |
midostaurin | down-regulates activity
chemical inhibition
|
KIT |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-258248 |
|
|
in vitro |
|
pmid |
sentence |
22037378 |
Our data set represents the most detailed comprehensive assessment of the reactivity of known and clinical kinase inhibitors across the kinome published to date. | The data also show that for at least 15 of the 27 kinases that are the primary, intended targets for the compounds tested and that are represented in the assay panel, selective inhibitors, as assessed by both absolute selectivity across the kinome and selectivity relative to the primary target, are among the 72 tested here. |
|
Publications: |
1 |
Organism: |
In Vitro |
Pathways: | Acute Myeloid Leukemia |
+ |
midostaurin | down-regulates activity
chemical inhibition
|
KDR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-261982 |
|
|
|
|
pmid |
sentence |
16969355 |
Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases |
|
Publications: |
1 |
+ |
midostaurin | down-regulates activity
chemical inhibition
|
FGR |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-261976 |
|
|
in vitro |
|
pmid |
sentence |
30069632 |
Midostaurin (PKC412, Rydapt®) is an oral multiple tyrosine kinase inhibitor. Main targets are the kinase domain receptor, vascular endothelial-, platelet derived-, and fibroblast growth factor receptor, stem cell factor receptor c-KIT, as well as mutated and wild-type FLT3 kinase |
|
Publications: |
1 |
Organism: |
In Vitro |
+ |
midostaurin | down-regulates activity
chemical inhibition
|
PRKCA |
0.8 |
Identifier |
Residue |
Sequence |
Organism |
Cell Line |
SIGNOR-261981 |
|
|
|
|
pmid |
sentence |
16969355 |
Midostaurin (PKC412A), N-benzoyl-staurosporine, potently inhibits protein kinase C alpha (PKCalpha), VEGFR2, KIT, PDGFR and FLT3 tyrosine kinases |
|
Publications: |
1 |